Brentuximab Vedotin (Recombinant) for IV Infusion – Special Drug Use Surveillance (All-case Surveillance) “Relapsed or Refractory CD30+ Hodgkin’s Lymphoma or Anaplastic Large Cell Lymphoma” (NCT02139592)
The purpose of this study is to evaluate the safety of the antibody-drug conjugate or ADC brentuximab vedotin (recombinant) for IV infusion (Adcetris® IV Infusion 50 mg) in patients with relapsed/refractory CD30+ Hodgkin lymphoma or anaplastic large cell lymphoma (ALCL) in the routine clinical setting, as well as to collect efficacy information for reference.
This trial is sponsored by Takeda Pharmaceuticals. 
- Relapsed or Refractory CD30+ Hodgkin Lymphoma
- Anaplastic Large Cell Lymphoma (ALCL)
- Phase: 0
- Estimated Enrollment: 140
- Start: April 2014
- Estimated Completion: June 2017
- Last verified: May 2014
Last Editorial review: July 15, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.